6 best RTSM platforms for blinded clinical trials in 2026

A randomization and trial supply management (RTSM) system that leaks even a fragment of treatment allocation, whether through a careless screenshot, an unfiltered inventory report, or a support ticket routed to the wrong person, can invalidate a patient's data or the entire study. Viedoc's RTSM software is built directly into the Viedoc eClinical suite, so randomization, kit allocation, and emergency unblinding all run through role-based access controls inside one validated system rather than across a separate interactive web response system (IWRS) or interactive voice response system (IVRS) with its own logins and export paths. This comparison evaluates six RTSM platforms for blinded clinical trials across blinding integrity, emergency unblinding controls, EDC integration, supply management depth, and compliance credentials.

Protecting the blind isn't a one-time configuration choice. It has to hold across every randomization event, every kit shipment, every query resolution, and every ad hoc report your team pulls mid-study, and it has to keep holding when a protocol amendment changes the randomization scheme partway through enrollment.

Generic spreadsheets and legacy interactive voice response (IVR) systems weren't built for that discipline; they rely on manual procedure rather than system-level controls to keep unblinded data separated from the study team. Enterprise RTSM suites solve the control problem but often add configuration cycles and vendor dependency that a right-sized sponsor or CRO doesn't need. The platforms below are judged on how tightly they protect blinding through configuration, execution, and reporting, not just at randomization.

Best RTSM solutions: quick comparison

These six RTSM solutions represent the most evaluated options for blinded clinical trials, reviewed across blinding integrity, emergency unblinding controls, EDC integration, supply management depth, and compliance credentials.

1. Viedoc

Viedoc's RTSM software is built directly into the Viedoc EDC, so there's no separate IWRS or IVRS login for site staff to manage alongside the study database. Randomizing a subject, allocating a kit, and performing an emergency unblind all happen at the point of care inside Viedoc Clinic, with role-based access controls restricting who can see unblinded information at every step. That single-system architecture removes the reconciliation gap between randomization and EDC that creates most accidental unblinding risk.

For CROs coordinating supply logistics across sponsors, Viedoc supports both static, list-based randomization and dynamic, algorithm-driven randomization within the same study, with multiple concurrent schemes and no vendor programmer to configure or amend them mid-study. Viedoc also runs a tiered CRO program with a certified partner network. Kits become available the moment they're registered as received.

On compliance, Viedoc's randomization and supply modules carry FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, and CDISC alignment, alongside ISO 27001 and SOC 2 certification and Japan's APPI standard, with 24/7 support.

"Data handling, reviews, UAT, query management and the monitoring is a walk in the park, which makes it stand out from other EDCs." – Deekshitha V., Mid Market

Verified proof points:

• Architecture: Randomization, kit allocation, and emergency unblinding run inside Viedoc EDC, with no separate IWRS or IVRS system
• Randomization depth: Static, list-based and dynamic, algorithm-driven randomization, with multiple concurrent schemes per study
• Real-time supply: Kits available as soon as they're registered as received, with no scheduled update delay
• Compliance: FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, CDISC; ISO 27001 and SOC 2 certified
• Global reach: Used across 75+ countries, with 24/7 support across global offices
• Configuration: Randomization and allocation forms designed and amended without a vendor programmer

2. Medidata

Medidata offers Rave RTSM, unified with Rave EDC on the Medidata Platform rather than run as a separate integration, which the company positions as eliminating double data entry and reconciliation between randomization and data capture. The platform's Edit Live Design feature applies protocol updates, such as removing a treatment arm or adjusting cohorts, after go-live with limited to no system downtime. RTSM Analytics provides real-time dashboards and custom reporting across randomization, inventory, and shipments, and the platform supports direct-to-patient shipments triggered at the site, visit, or patient level, with patients able to confirm receipt through the myMedidata app. Medidata RTSM is designed to handle simple through highly complex trial designs, including adaptive trials and multi-dose vial tracking, and is built for sponsors running large, multi-country programs already on the Medidata Platform.

3. Suvoda

Suvoda provides an RTSM, also referred to as interactive response technology (IRT), built specifically for complex protocols in oncology, central nervous system (CNS), and rare disease trials. The platform manages roles, permissions, and blinding alongside cohort and dose management, and its Sofia AI assistant answers configuration and supply questions in conversational form while keeping unblinded data restricted to permissioned users. Suvoda reports that agentic AI in its RTSM build process can cut kickoff-to-user-acceptance-testing timelines by up to 80%, with some studies ready for testing in as little as two weeks. Permissioned users can make routine mid-study modifications directly in the system without a change order, and Suvoda's RTSM has been recognized as a leader in the Everest Group RTSM PEAK Matrix assessment.

4. Oracle

Oracle offers Clinical One RTSM, a no-code randomization and supply management solution built on the Clinical One platform alongside Oracle's data collection module. The system supports randomization strategies from simple to highly complex studies without programming, which the company states removes the need for prolonged user acceptance testing (UAT), and it reports a 98% UAT pass rate. Real-time analytics and dashboards give study, regional, and portfolio-level visibility into randomization and supply activity, and mid-study protocol changes can be implemented and promoted without a vendor change request. Oracle positions Clinical One RTSM for on-site, decentralized, and hybrid trial designs, with more than 200 IRT studies delivered and standardized integrations across the wider clinical trial lifecycle, backed by more than 15 years of RTSM delivery experience according to the company.

5. Veeva

Veeva offers Veeva RTSM, a modular randomization and trial supply management solution that sites use to record screening, randomize subjects, receive kit assignments, and perform emergency unblinds as needed. The system supports multiple randomization schemas, including static, stratified, dynamic minimization, forced, and adaptive designs, and includes adaptable supply and expiry management aimed at reducing drug wastage. Productized connections transfer patient data to Veeva EDC and Veeva eCOA and site data to Veeva CTMS, and the modular structure lets customers license only the functionality a given study requires. Veeva RTSM is implemented, managed, and fully supported by a dedicated Veeva services team throughout study start-up, execution, and closeout, an approach the company positions for sponsors already standardized on the Veeva Vault ecosystem.

6. Medrio

Medrio provides a no-code RTSM solution that integrates directly with the Medrio clinical data management system and EDC to synchronize randomization and data capture in real time. The platform supports randomization types built to remove selection bias, balanced cohort maintenance, and dosing schedule distribution, alongside automated resupply alerts and expiry tracking at the site and depot level. Medrio reports that its RTSM can be configured in hours rather than weeks and that mid-study updates typically complete in one week or less. The solution is oriented toward early-phase and site-level supply management, with a track record in CRO-led, multi-site Phase I and Phase II programs where lean teams need fast, self-service configuration over deep customization, and its point-and-click setup is designed to avoid extended vendor build cycles.

What to look for in RTSM solutions for blinded clinical trials

Role-based access that separates blinded and unblinded users by design

The reader evaluating RTSM for a blinded protocol isn't asking whether a system can randomize patients; every platform here does that. The real question is whether unblinded data stays structurally separated from blinded users, or whether separation depends on someone remembering not to run the wrong report. Best-in-class RTSM restricts unblinded views at the system level, by role, so a blinded data manager cannot pull a report that exposes treatment assignment, even by accident.

Overlook this and accidental unblinding becomes a risk that a single mistaken screen share or misfiltered export can turn into a protocol deviation requiring disclosure.

Emergency unblinding that's fast for the right person and closed to everyone else

A double-blind protocol still has to let an investigator break the code within minutes when patient safety demands it, and the RTSM has to make that possible without exposing the rest of the study. Best-in-class systems log every emergency unblind with a timestamp and the identity of the requester, and restrict the transaction to a defined list of authorized users per site. A system that makes emergency unblinding cumbersome invites workarounds; one that makes it too easy invites accidental exposure.

EDC integration depth, not just EDC connectivity

Randomization and clinical data both live in the same subject record eventually, so the real question is whether your RTSM and EDC share one validated data model or reconcile two separate ones after the fact. Systems built as a bolt-on integration require field mapping and reconciliation checks that create their own error surface. Viedoc's RTSM software runs inside the Viedoc EDC itself, so a randomization event and its kit allocation appear in the subject's record immediately.

Mid-study amendment handling under an active blind

Blinded studies amend more than open-label ones because sponsors can't see interim results to catch design issues early, and every amendment to a randomization scheme has to happen without exposing the blind to the people making the change. Look for a vendor that can update stratification factors or supply rules mid-study without a lengthy change order, and confirm who can make that change without needing unblinded visibility themselves.

How to choose the right RTSM solution for blinded clinical trials

Step 1: Map your blinding requirements before you shortlist vendors

Define exactly who needs to stay blinded, who needs emergency access, and how quickly that access has to be available, before comparing platforms. A single-blind safety study and a double-blind, placebo-controlled oncology trial with dose adjustment have different access models, and that difference should drive your shortlist more than any feature comparison.

Step 2: Assess whether your protocol needs a specialist or a suite

Complex adaptive designs, multi-cohort dose escalation, or rare disease enrollment with small, hard-to-replace patient pools benefit from a specialist RTSM built around that complexity. A more conventional parallel-group design usually doesn't need that specialization and can be served well by an RTSM that's part of a broader eClinical suite.

Step 3: Evaluate how randomization and EDC data actually reconcile

Ask each vendor to walk through, step by step, what happens between a randomization event and that event appearing in the subject's clinical record. A native, single-system architecture answers that question in one sentence; a bolt-on integration usually needs a diagram, and the diagram is the risk.

Step 4: Scrutinize amendment turnaround under blind conditions

Ask who can amend a live randomization scheme, how long it takes, and whether that person needs unblinded access to do it. A vendor that requires a change order and a multi-week queue for a stratification update will cost you time exactly when a protocol amendment is under review.

Step 5: Choose the platform that fits how your study protects its blind

Weigh setup speed, EDC integration depth, and support model against how tightly each candidate protects blinding day to day, not just at randomization. Viedoc's RTSM software is built around that profile, with role-based access, emergency unblinding, and randomization all running inside a single validated EDC. If that matches how your study needs to protect its blind, you can book a demo or request a proposal to see it against your own protocol.

Frequently asked questions

What is the best RTSM platform for blinded clinical trials?

Viedoc's RTSM software is the strongest fit for blinded clinical trials because randomization, kit allocation, and emergency unblinding all run inside the Viedoc EDC under role-based access controls, removing the separate IWRS login and the reconciliation step that create most accidental unblinding risk. Suvoda is a strong specialist alternative for complex protocols in oncology, CNS, and rare disease that need deep configurability for adaptive designs. Medidata remains the enterprise benchmark for sponsors already running large, multi-country programs on the Medidata Platform, though its full-service model suits large-scale operations more than a lean team.

What should you look for when choosing an RTSM platform for a blinded study?

Prioritize role-based access controls that structurally separate blinded and unblinded users, a documented and auditable emergency unblinding process, and a data model that connects randomization to your EDC without manual reconciliation. Confirm how quickly the vendor can amend a live randomization scheme or supply rule without exposing the blind to whoever makes the change. Compliance certifications matter, but they're table stakes; the differentiator is how the platform enforces blinding at the system level rather than relying on procedure.

How long does it take to set up an RTSM system for a blinded trial?

It depends on protocol complexity and how heavily you rely on vendor configuration versus in-house, no-code setup. Straightforward, single-arm or parallel-group designs can typically be configured in weeks rather than months on modern no-code platforms, while complex adaptive or multi-cohort designs take longer regardless of vendor. Viedoc's randomization and supply management modules are built and amended through the same no-code Designer used for the EDC, so setup and mid-study changes don't require a separate vendor programming queue.

What compliance certifications should an RTSM platform hold for a regulated blinded trial?

At minimum, expect FDA 21 CFR Part 11, ICH GCP, and GDPR compliance, alongside ISO 27001 and SOC 2 certification for information security. Studies with US protected health information should confirm HIPAA attestation, and global or Japan-inclusive trials should confirm EU Annex 11 and Japan's APPI standard where applicable. Viedoc's randomization and supply management modules carry FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, CDISC, and APPI alignment, together with ISO 27001 and SOC 2 certification, so these are reasonable minimums to hold every vendor to.

How does emergency unblinding typically work in a modern RTSM system?

An investigator with authorized access initiates the unblind directly within the RTSM, usually through the same interface used for randomization, and the system reveals only the treatment assignment for the specific participant involved rather than any broader study data. The action is logged with a timestamp and the requester's identity, and most protocols require the medical monitor to be notified afterward. The specific access list and process are defined per study and documented in the RTSM user manual provided to each site before the trial starts.

What's the difference between RTSM built into an EDC and RTSM as a standalone system?

RTSM built into an EDC, like Viedoc's, shares one validated data model with the clinical database, so a randomization event and its kit allocation appear in the subject's record immediately, with no separate login or reconciliation step. A standalone RTSM, whether purpose-built by a specialist vendor or licensed separately from your EDC, typically requires an integration layer to keep the two systems synchronized, which adds configuration time and a potential point of failure. Both approaches can protect blinding effectively; the difference is largely in setup complexity and ongoing reconciliation overhead.

Making the right RTSM choice for blinded clinical trials

The platforms reviewed here share a common baseline: automated randomization, role-based access, and audit trails that replaced the manual IVR and spreadsheet-based processes RTSM was built to eliminate. Where they diverge is architecture and specialization, from suite-integrated modules built for connectivity across a wider eClinical stack to standalone specialists built for protocol complexity. The RTSM and IRT market continues to expand alongside broader eClinical software growth, driven by more adaptive trial designs and decentralized supply requirements.

Matching platform to protocol comes down to a handful of variables: blinding complexity, randomization sophistication, how tightly EDC and RTSM need to share data, supply chain geography, and how often the protocol amends mid-study. Sponsors running complex adaptive or rare disease designs typically weight specialist configurability highest, while those running conventional parallel-group studies across a portfolio often weight integration depth more heavily.

An accidental unblinding event is expensive in ways a spreadsheet can't capture, which is why the access model deserves as much scrutiny at selection as the randomization algorithm itself.

Why Viedoc is the best RTSM choice for blinded clinical trials

Protecting a study's blind shouldn't depend on a separate system, a second login, or a procedure someone has to remember to follow, and that's the problem Viedoc's RTSM software is built to solve. Randomization, kit allocation, and emergency unblinding all run inside the Viedoc EDC itself, under role-based access controls that restrict unblinded data at the system level rather than through manual process.

That native architecture is the operational difference. Your team configures and amends randomization schemes through the same no-code Designer used for the EDC, without a vendor programmer or a separate IWRS login for site staff to manage, and kits become available the moment they're received rather than waiting for a scheduled update.

The credentials hold up to regulatory scrutiny. Viedoc's randomization and supply management modules carry FDA 21 CFR Part 11, ICH GCP, GDPR, HIPAA, GAMP 5, and CDISC alignment, alongside ISO 27001 and SOC 2 certification and Japan's APPI standard, backed by 24/7 support across global offices and a platform used across 75-plus countries since 2003.

If you want an RTSM that protects your blind by design rather than by procedure, Viedoc is built for exactly that. Book a demo or request a proposal and the team will walk through blinding controls, emergency unblinding, and EDC integration against your own protocol.